U.S. Brain Tumor Market Summary

The U.S. brain tumor market size was estimated at USD 1.7 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 9.87% from 2025 to 2034. This growth is primarily attributed to the increasing prevalence of brain cancer and the rising number of brain tumor diagnoses across the country. For example, data published by the National Brain Tumor Society estimates that approximately one million Americans are currently living with a primary brain tumor. This significant patient population highlights the urgent need for effective and diverse treatment options across different tumor types.

Among these diagnosed tumors, around 72% were estimated to be benign and 28% malignant in 2023, reflecting a wide spectrum of treatment approaches depending on tumor severity and progression. Non-malignant meningiomas emerged as the most common form of primary non-malignant brain tumors, accounting for about 39.7% of all brain tumors and 55.4% of all non-malignant tumors. This classification emphasizes the importance of tailored therapies and clinical strategies to meet varying patient needs and manage disease outcomes more effectively.

Key Market Trends & Insights

• Market growth is further propelled by increasing funding and investment activities from public and private sectors alike. In January 2025, GT Medical Technologies, Inc. secured USD 37 million in a Series D financing round aimed at expanding the reach of GammaTile, a U.S.-based radiation therapy innovation specifically developed for patients with operable brain tumors. Such developments underscore a growing interest in advanced technologies and therapeutic approaches within the treatment landscape, enhancing survival rates and overall patient outcomes.
• In 2024, the malignant tumor segment held the largest revenue share at 67.2%. This dominance is driven by the higher prevalence of life-threatening brain cancers such as glioblastoma and other high-grade malignant tumors. According to the National Brain Tumor Society, brain cancer ranked as the 10th leading cause of cancer-related deaths in 2023. This underscores the critical need for intensive research, early diagnosis, and innovative treatment protocols to combat high-mortality tumors effectively.
• The surgery segment led the market in 2024, holding the largest market share. This is due to its central role in the treatment of many brain tumors, especially aggressive or malignant types like glioblastomas. Surgical procedures remain a primary line of treatment, particularly when tumors are accessible and operable. Moreover, continued advancements in neurosurgical technologies, including image-guided surgery, minimally invasive techniques, and robotic-assisted procedures, have significantly improved surgical safety, precision, and post-operative outcomes, thereby driving the increased adoption of surgical interventions in clinical practice.

Order a free sample PDF of the U.S. Brain Tumor Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 1.7 billion
• 2034 Projected Market Size: USD 4.35 billion
• CAGR (2025 - 2034): 9.87%

Key Companies & Market Share Insights

Varian Medical Systems, Inc. (Siemens Healthineers), Accuray Incorporated, Elekta, GT Medical Technologies, Inc., Novocure, and Aesculap, Inc. - a B. Braun company, are some of the major players in the U.S. brain tumor market. These companies are expanding their portfolios in this sector and acquiring smaller firms to strengthen their competitive edge in the rapidly growing industry. Moreover, industry players are launching advanced products to meet the increasing demand.

Key Players

• GT Medical Technologies, Inc.
• Novocure
• ZAP Surgical Systems, Inc.
• Aesculap, Inc. - a B. Braun company
• Accuray Incorporated
• Carthera
• Alpheus Medical Inc.
• Alpha Tau Medical Ltd
• Elekta
• IMRIS Inc.
• Medtronic
• Monteris
• Openwater
• Acoustic MedSystems, Inc.
• NaviFUS Corp
• Insightec
• Varian Medical Systems, Inc. (Siemens Healthineers)
• RefleXion
• MagnetTx Oncology Solutions Ltd.
• NICO Corporation (Stryker)
• Terumo Interventional Systems
• Boston Scientific Corporation
• Koninklijke Philips N.V.
• IBA Worldwide

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

In conclusion, the U.S. brain tumor market is set to expand significantly through 2034, driven by a growing patient base, rising diagnoses, and greater emphasis on innovative treatments. The market is fueled by rising incidences of malignant tumors like glioblastoma, as well as significant investment in radiation and surgical therapies. Advancements in surgical precision and technology, coupled with increasing financial support for therapeutic innovation, are improving treatment outcomes. As awareness and early detection continue to grow, the demand for specialized, effective brain tumor treatments will rise, ensuring sustained growth and a dynamic shift in the country’s neuro-oncology landscape.